Business Context and Reporting Period
This Form 8-K is filed by Entero Therapeutics, Inc. (trading symbol: ENTO) on September 6, 2024. The report addresses a regulatory notice regarding the company's continued listing status on The Nasdaq Capital Market. The registrant is incorporated in Delaware and maintains its principal executive offices in Boca Raton, Florida.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on compliance with stock exchange listing standards.
Material Changes
The material event reported is the receipt of a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. The notice indicates that the company's common stock failed to maintain a minimum closing bid price of $1.00 per share for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
Guidance, Outlook, and Risks
- Compliance Period: The company has been granted an initial 180-calendar day compliance period ending March 5, 2025, to regain compliance.
- Remediation Path: Compliance can be achieved if the closing bid price reaches or exceeds $1.00 per share for a minimum of 10 consecutive business days before the deadline.
- Extension Possibility: If the company fails to regain compliance by March 5, 2025, Nasdaq may grant a second 180-day period, provided the company meets other listing standards (e.g., market value of publicly-held shares) and notifies Nasdaq of its intent to cure.
- Risks: There is no assurance the company will regain compliance. Failure to do so within the allotted periods could result in delisting. The company retains the right to appeal a delisting determination to a Nasdaq hearings panel.
- Current Status: The notice has no immediate effect on the listing status; the stock remains fully effective on The Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current closing bid price of ENTO stock relative to the $1.00 threshold.
- Monitor the company's progress toward achieving 10 consecutive days of trading at or above $1.00 before March 5, 2025.
- Review future filings for any announcements regarding a reverse stock split or other capital structure changes intended to address the bid price deficiency.
- Check for any subsequent notices from Nasdaq regarding the company's intent to utilize a second compliance period.